Skip to main content
SpringerLink
Log in

Crosstalk of Immuno-Oncology and Metabolism: Influence of Akkermansia muciniphila and Personalized Therapy Approach

  • Chapter
  • First Online:
Immuno-Oncology Crosstalk and Metabolism

Abstract

A healthy cell can turn into a cancerous cell, which requires a complex mechanism, such as genetic and epigenetic modification. This leads to an increase in cell size and growth, differentiation, and uncontrolled proliferation and eventually becomes an immortal cell. These processes are mainly influenced by “reprogramming of cellular metabolism” and this sets up the cancer cells to evade the natural destruction process by lymphocytes (T and B), macrophages, and natural killer cells. Over the last decade, researchers have explored the role of microbiota in regulating cancer immunometabolism, suggesting an unprecedented role in cancer progression and regression. In particular, some microbes act as a probiotic—a live microorganism that produces beneficial effects when administered, mainly Lactobacillus and Bifidobacterium spp. A new addition to this list is Akkermansia muciniphila (A. muciniphila). In this review, we emphasize the importance of A. muciniphila and the personalized therapy approach in the crosstalk of immuno-oncology and metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  3. Guo C et al (2019) Immunometabolism: a new target for improving cancer immunotherapy. Adv Cancer Res 143:195–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2(10):881–898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Romero-Garcia S et al (2011) Tumor cell metabolism: an integral view. Cancer Biol Ther 12(11):939–948

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. O’Neill LA, Kishton RJ, Rathmell J (2016) A guide to immunometabolism for immunologists. Nat Rev Immunol 16(9):553–565

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. O’Neill LA, Pearce EJ (2016) Immunometabolism governs dendritic cell and macrophage function. J Exp Med 213(1):15–23

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Renner K et al (2015) Metabolic plasticity of human T cells: preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions. Eur J Immunol 45(9):2504–2516

    Article  CAS  PubMed  Google Scholar 

  9. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314

    Article  CAS  PubMed  Google Scholar 

  10. Busk M et al (2011) Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol 99(3):404–411

    Article  CAS  PubMed  Google Scholar 

  11. Voelxen NF et al (2018) Comparative metabolic analysis in head and neck cancer and the normal gingiva. Clin Oral Investig 22(2):1033–1043

    Article  PubMed  Google Scholar 

  12. Almuhaideb A, Papathanasiou N, Bomanji J (2011) 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 31(1):3–13

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chang CH et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cascone T et al (2018) Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab 27(5):977–987.e4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Szablewski L (2013) Expression of glucose transporters in cancers. Biochim Biophys Acta 1835(2):164–169

    CAS  PubMed  Google Scholar 

  16. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654–662

    Article  CAS  PubMed  Google Scholar 

  17. Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35(1):9–26

    Article  CAS  PubMed  Google Scholar 

  18. Furuta E et al (2010) Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805(2):141–152

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Mates JM et al (2009) Glutamine homeostasis and mitochondrial dynamics. Int J Biochem Cell Biol 41(10):2051–2061

    Article  CAS  PubMed  Google Scholar 

  20. Vettore L, Westbrook RL, Tennant DA (2020) New aspects of amino acid metabolism in cancer. Br J Cancer 122(2):150–156

    Article  CAS  PubMed  Google Scholar 

  21. Eagle H (1955) Nutrition needs of mammalian cells in tissue culture. Science 122(3168):501–514

    Article  CAS  PubMed  Google Scholar 

  22. Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8):427–433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bolzoni M et al (2016) Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood 128(5):667–679

    Article  CAS  PubMed  Google Scholar 

  24. Furusawa A et al (2018) Ovarian cancer therapeutic potential of glutamine depletion based on GS expression. Carcinogenesis 39(6):758–766

    Article  CAS  PubMed  Google Scholar 

  25. Chiu M et al (2018) Oligodendroglioma cells lack glutamine synthetase and are auxotrophic for glutamine, but do not depend on glutamine anaplerosis for growth. Int J Mol Sci 19(4)

    Google Scholar 

  26. Wang JJ, Lei KF, Han F (2018) Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci 22(12):3855–3864

    PubMed  Google Scholar 

  27. Helmy KY et al (2013) Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv 4(10):1307–1320

    Article  CAS  PubMed  Google Scholar 

  28. Korgaonkar N, Yadav KS (2019) Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. Life Sci 239:117060

    Article  CAS  PubMed  Google Scholar 

  29. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3):184–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Reifenberger G et al (2017) Advances in the molecular genetics of gliomas—implications for classification and therapy. Nat Rev Clin Oncol 14(7):434–452

    Article  CAS  PubMed  Google Scholar 

  31. Lemjabbar-Alaoui H et al (2015) Lung cancer: biology and treatment options. Biochim Biophys Acta 1856(2):189–210

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Ahdoot M et al (2020) MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 382(10):917–928

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sheill G et al (2020) Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial. BMC Cancer 20(1):321

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bregni G et al (2020) Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice. Cancer Treat Rev 83:101948

    Article  CAS  PubMed  Google Scholar 

  35. Turgeon GA et al (2019) Radiotherapy and immunotherapy: a synergistic effect in cancer care. Med J Aust 210(1):47–53

    Article  PubMed  Google Scholar 

  36. Marcello M et al (2020) Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. Radiother Oncol 150:281–292

    Article  CAS  PubMed  Google Scholar 

  37. Kauff DW et al (2020) Fecal incontinence after total mesorectal excision for rectal cancer-impact of potential risk factors and pelvic intraoperative neuromonitoring. World J Surg Oncol 18(1):12

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lohse I, Brothers SP (2020) Pathogenesis and treatment of pancreatic cancer related pain. Anticancer Res 40(4):1789–1796

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Franzosa EA et al (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 4(2):293–305

    Article  CAS  PubMed  Google Scholar 

  40. Hu S et al (2021) Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD. Gut 70(2):285–296

    CAS  PubMed  Google Scholar 

  41. Regnier M et al (2021) Gut microbiome, endocrine control of gut barrier function and metabolic diseases. J Endocrinol 248(2):R67–R82

    Article  CAS  PubMed  Google Scholar 

  42. Tripathi A et al (2018) The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15(7):397–411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jobin C (2018) Precision medicine using microbiota. Science 359(6371):32–34

    Article  CAS  PubMed  Google Scholar 

  44. Alexander JL et al (2017) Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 14(6):356–365

    Article  CAS  PubMed  Google Scholar 

  45. Gopalakrishnan V et al (2018) The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33(4):570–580

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Elkrief A et al (2019) The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes 10(3):424–428

    Article  CAS  PubMed  Google Scholar 

  47. Appelbe OK et al (2017) Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide. J Control Release 266:248–255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Panebianco C, Andriulli A, Pazienza V (2018) Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6(1):92

    Article  PubMed  PubMed Central  Google Scholar 

  49. Iida N et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342(6161):967–970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26(17):3009–3025

    Article  CAS  PubMed  Google Scholar 

  51. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rittmeyer A et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265

    Article  PubMed  Google Scholar 

  53. Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103

    Article  CAS  PubMed  Google Scholar 

  54. Temraz S et al (2019) Gut microbiome: a promising biomarker for immunotherapy in colorectal Cancer. Int J Mol Sci 20(17)

    Google Scholar 

  55. Shuwen H et al (2020) Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer. Microb Pathog 149:104343

    Article  PubMed  CAS  Google Scholar 

  56. Zhang M et al (2020) The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy. Ann Palliat Med 9(6):4211–4227

    Article  PubMed  Google Scholar 

  57. Mini E et al (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7–v12

    Article  PubMed  Google Scholar 

  58. Vande Voorde J, Balzarini J, Liekens S (2014) Mycoplasmas and cancer: focus on nucleoside metabolism. EXCLI J 13:300–322

    PubMed  PubMed Central  Google Scholar 

  59. Geller LT et al (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156–1160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78(4):661–671

    Article  CAS  PubMed  Google Scholar 

  61. Viaud S et al (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161):971–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Daillere R et al (2016) Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45(4):931–943

    Article  CAS  PubMed  Google Scholar 

  63. Jang SE et al (2013) Lactobacillus casei HY7213 ameliorates cyclophosphamide-induced immunosuppression in mice by activating NK, cytotoxic T cells and macrophages. Immunopharmacol Immunotoxicol 35(3):396–402

    Article  CAS  PubMed  Google Scholar 

  64. Jang SE et al (2013) Lactobacillus plantarum HY7712 ameliorates cyclophosphamide-induced immunosuppression in mice. J Microbiol Biotechnol 23(3):414–421

    Article  PubMed  Google Scholar 

  65. Maroof H et al (2012) Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 32(6):1353–1359

    Article  CAS  PubMed  Google Scholar 

  66. Petty RD, Cassidy J (2004) Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets 4(2):191–204

    Article  CAS  PubMed  Google Scholar 

  67. Mindt S et al (2019) Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. Clin Chem Lab Med 57(7):1012–1016

    Article  CAS  PubMed  Google Scholar 

  68. Garcia-Gonzalez AP et al (2017) Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell 169(3):431–441.e8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hashemi Goradel N et al (2019) Fusobacterium nucleatum and colorectal cancer: a mechanistic overview. J Cell Physiol 234(3):2337–2344

    Article  CAS  PubMed  Google Scholar 

  70. Chen Y et al (2020) Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics 10(1):323–339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Luo K et al (2019) Fusobacterium nucleatum, the communication with colorectal cancer. Biomed Pharmacother 116:108988

    Article  CAS  PubMed  Google Scholar 

  72. Li M, Chen WD, Wang YD (2020) The roles of the gut microbiota-miRNA interaction in the host pathophysiology. Mol Med 26(1):101

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Neradil J, Pavlasova G, Veselska R (2012) New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol 25 Suppl 2:2S87–2S92

    CAS  PubMed  Google Scholar 

  74. Zhou B et al (2018) Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 33:122–133

    Article  PubMed  PubMed Central  Google Scholar 

  75. Frank M et al (2015) TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 194(4):1983–1995

    Article  CAS  PubMed  Google Scholar 

  76. Nishida A et al (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11(1):1–10

    Article  PubMed  Google Scholar 

  77. Hills RD Jr et al (2019) Gut microbiome: profound implications for diet and disease. Nutrients 11(7):1613

    Article  CAS  PubMed Central  Google Scholar 

  78. Di Marzo V, Silvestri C (2019) Lifestyle and metabolic syndrome: contribution of the Endocannabinoidome. Nutrients 11(8):1956

    Article  CAS  PubMed Central  Google Scholar 

  79. Reid G (2016) Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 30(1):17–25

    Article  CAS  PubMed  Google Scholar 

  80. Goldin BR, Gorbach SL (1980) Effect of lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. J Natl Cancer Inst 64(2):263–265

    Article  CAS  PubMed  Google Scholar 

  81. Slizewska K, Markowiak-Kopec P, Slizewska W (2020) The role of probiotics in cancer prevention. Cancers (Basel) 13(1):20

    Article  CAS  Google Scholar 

  82. Daisley BA et al (2020) Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun 11(1):4822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Chen Z et al (2020) Akkermansia muciniphila enhances the antitumor effect of cisplatin in Lewis lung cancer mice. J Immunol Res 2020:2969287

    Article  PubMed  PubMed Central  Google Scholar 

  84. Maldonado Galdeano C et al (2019) Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab 74(2):115–124

    Article  CAS  PubMed  Google Scholar 

  85. Cerdo T et al (2019) The role of probiotics and prebiotics in the prevention and treatment of obesity. Nutrients 11(3):635

    Article  CAS  PubMed Central  Google Scholar 

  86. Naghmouchi K et al (2020) Lactobacillus fermentum: a bacterial species with potential for food preservation and biomedical applications. Crit Rev Food Sci Nutr 60(20):3387–3399

    Article  CAS  PubMed  Google Scholar 

  87. Arena MP et al (2018) Immunobiosis and probiosis: antimicrobial activity of lactic acid bacteria with a focus on their antiviral and antifungal properties. Appl Microbiol Biotechnol 102(23):9949–9958

    Article  CAS  PubMed  Google Scholar 

  88. Degnan FH (2008) The US Food and Drug Administration and probiotics: regulatory categorization. Clin Infect Dis 46(Suppl 2):S133–S136; discussion S144-51

    Article  PubMed  Google Scholar 

  89. Gorska A et al (2019) Probiotic bacteria: a promising tool in cancer prevention and therapy. Curr Microbiol 76(8):939–949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Wada M et al (2010) Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 18(6):751–759

    Article  PubMed  Google Scholar 

  91. Asadollahi P et al (2020) Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis. PLoS One 15(5):e0232930

    Article  PubMed  CAS  Google Scholar 

  92. Sanctis VDE et al (2019) Lactobacillus brevis CD2 for prevention of Oral mucositis in patients with head and neck tumors: a multicentric randomized study. Anticancer Res 39(4):1935–1942

    Article  CAS  Google Scholar 

  93. Gui QF et al (2015) Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14(2):5642–5651

    Article  PubMed  Google Scholar 

  94. Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97

    Article  CAS  PubMed  Google Scholar 

  95. Naito Y, Uchiyama K, Takagi T (2018) A next-generation beneficial microbe: Akkermansia muciniphila. J Clin Biochem Nutr 63(1):33–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Wang L et al (2020) A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) T cells in mice. Gut 69(11):1988–1997

    Article  CAS  PubMed  Google Scholar 

  97. Davani-Davari D et al (2019) Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 8(3):92

    Article  CAS  PubMed Central  Google Scholar 

  98. Kumar V et al (2012) Dietary roles of non-starch polysaccharides in human nutrition: a review. Crit Rev Food Sci Nutr 52(10):899–935

    Article  CAS  PubMed  Google Scholar 

  99. Schroeder BO et al (2018) Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23(1):27–40.e7

    Article  CAS  PubMed  Google Scholar 

  100. Sebastian C, Mostoslavsky R (2014) Untangling the fiber yarn: butyrate feeds Warburg to suppress colorectal cancer. Cancer Discov 4(12):1368–1370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Sasidharan BK et al (2019) A phase 2 randomized controlled trial of oral resistant starch supplements in the prevention of acute radiation proctitis in patients treated for cervical cancer. J Cancer Res Ther 15(6):1383–1391

    Article  PubMed  Google Scholar 

  102. Bruno-Barcena JM, Azcarate-Peril MA (2015) Galacto-oligosaccharides and colorectal cancer: feeding our intestinal probiome. J Funct Foods 12:92–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Watson H et al (2018) A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 67(11):1974–1983

    Article  CAS  PubMed  Google Scholar 

  104. Garcia-So J et al (2019) Omega-3 fatty acids suppress Fusobacterium nucleatum-induced placental inflammation originating from maternal endothelial cells. JCI Insight 4(3):e125436

    Article  PubMed Central  Google Scholar 

  105. Segura Munoz RR et al (2020) Stearidonic-enriched soybean oil modulates obesity, glucose metabolism, and fatty acid profiles independently of Akkermansia muciniphila. Mol Nutr Food Res 64(17):e2000162

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Wegh CAM et al (2019) Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci 20(19):4673

    Article  CAS  PubMed Central  Google Scholar 

  107. Rad AH et al (2021) Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment. Crit Rev Food Sci Nutr 61(11):1787–1803

    Article  CAS  PubMed  Google Scholar 

  108. Whitford EJ et al (2009) Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-fluorouracil (5-FU). Cancer Biol Ther 8(6):505–511

    Article  CAS  PubMed  Google Scholar 

  109. Prisciandaro LD et al (2011) Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther 11(7):671–677

    Article  CAS  PubMed  Google Scholar 

  110. An J, Ha EM (2016) Combination therapy of Lactobacillus plantarum supernatant and 5-Fluouracil increases chemosensitivity in colorectal cancer cells. J Microbiol Biotechnol 26(8):1490–1503

    Article  CAS  PubMed  Google Scholar 

  111. Zhao Y et al (2021) Dual gate-controlled therapeutics for overcoming bacterium-induced drug resistance and potentiating cancer immunotherapy. Angew Chem Int Ed Engl 60(25):14013–14021

    Article  PubMed  CAS  Google Scholar 

  112. Flieger D et al (2007) Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72(1–2):10–16

    Article  CAS  PubMed  Google Scholar 

  113. Vetizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Bobay LM, Ochman H (2018) Biological species in the viral world. Proc Natl Acad Sci U S A 115(23):6040–6045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Fluckiger A et al (2020) Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369(6506):936–942

    Article  CAS  PubMed  Google Scholar 

  116. Derrien M et al (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54(Pt 5):1469–1476

    Article  CAS  PubMed  Google Scholar 

  117. Ouwerkerk JP et al (2016) Akkermansia glycaniphila sp. Nov., an anaerobic mucin-degrading bacterium isolated from reticulated python faeces. Int J Syst Evol Microbiol 66(11):4614–4620

    Article  CAS  PubMed  Google Scholar 

  118. Ley RE et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023

    Article  CAS  PubMed  Google Scholar 

  119. Salzman NH et al (2002) Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology (Reading) 148(Pt 11):3651–3660

    Article  CAS  Google Scholar 

  120. Sonoyama K et al (2009) Response of gut microbiota to fasting and hibernation in Syrian hamsters. Appl Environ Microbiol 75(20):6451–6456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Zhang T et al (2019) Akkermansia muciniphila is a promising probiotic. Microb Biotechnol 12(6):1109–1125

    Article  PubMed  PubMed Central  Google Scholar 

  122. Derrien M, Belzer C, de Vos WM (2017) Akkermansia muciniphila and its role in regulating host functions. Microb Pathog 106:171–181

    Article  PubMed  Google Scholar 

  123. Brahe LK et al (2015) Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diabetes 5:e159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Collado MC et al (2010) Effect of mother’s weight on infant’s microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. Am J Clin Nutr 92(5):1023–1030

    Article  CAS  PubMed  Google Scholar 

  125. Hanninen A et al (2018) Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 67(8):1445–1453

    Article  PubMed  CAS  Google Scholar 

  126. Plovier H et al (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23(1):107–113

    Article  CAS  PubMed  Google Scholar 

  127. Li J et al (2016) Akkermansia Muciniphila protects against atherosclerosis by preventing metabolic Endotoxemia-induced inflammation in Apoe−/− mice. Circulation 133(24):2434–2446

    Article  CAS  PubMed  Google Scholar 

  128. van der Lugt B et al (2019) Akkermansia muciniphila ameliorates the age-related decline in colonic mucus thickness and attenuates immune activation in accelerated aging Ercc1 (−/Delta7) mice. Immun Ageing 16:6

    Article  PubMed  PubMed Central  Google Scholar 

  129. Olivier-Van Stichelen S, Rother KI, Hanover JA (2019) Maternal exposure to non-nutritive sweeteners impacts Progeny’s metabolism and microbiome. Front Microbiol 10:1360

    Article  PubMed  PubMed Central  Google Scholar 

  130. Zhao S et al (2017) Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol 58(1):1–14

    Article  PubMed  Google Scholar 

  131. Grander C et al (2018) Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67(5):891–901

    Article  PubMed  CAS  Google Scholar 

  132. Kim S et al (2020) Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis. Appl Environ Microbiol 86(7)

    Google Scholar 

  133. Ottman N et al (2017) Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One 12(3):e0173004

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Bedarf JR et al (2017) Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson’s disease patients. Genome Med 9(1):39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. de la Cuesta-Zuluaga J et al (2017) Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40(1):54–62

    Article  PubMed  CAS  Google Scholar 

  136. Panebianco C et al (2018) Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemother Pharmacol 81(4):773–782

    Article  CAS  PubMed  Google Scholar 

  137. Ramakrishna C et al (2019) Dominant role of the gut microbiota in chemotherapy induced neuropathic pain. Sci Rep 9(1):20324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Su H et al (2020) Andrographolide exerts antihyperglycemic effect through strengthening intestinal barrier function and increasing microbial composition of Akkermansia muciniphila. Oxid Med Cell Longev 2020:6538930

    Article  PubMed  PubMed Central  Google Scholar 

  139. Wang L et al (2019) Puerarin prevents high-fat diet-induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice. PLoS One 14(6):e0218490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Fujisaka S et al (2020) Bofutsushosan improves gut barrier function with a bloom of Akkermansia muciniphila and improves glucose metabolism in mice with diet-induced obesity. Sci Rep 10(1):5544

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  141. Chen ML et al (2016) Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio 7(2):e02210–e02215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Shin NR et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63(5):727–735

    Article  CAS  PubMed  Google Scholar 

  143. Everard A et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110(22):9066–9071

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Ganesh BP et al (2013) Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella typhimurium-infected gnotobiotic mice. PLoS One 8(9):e74963

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Farhana L et al (2018) Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans. World J Gastrointest Pathophysiol 9(2):47–58

    Article  PubMed  PubMed Central  Google Scholar 

  146. Lapidot Y et al (2020) Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma. mSystems 5(3):e00153–e00120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Snider EJ et al (2019) Alterations to the esophageal microbiome associated with progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Epidemiol Biomark Prev 28(10):1687–1693

    Article  Google Scholar 

  148. Jiang H et al (2019) Intestinal flora disruption and novel biomarkers associated with nasopharyngeal carcinoma. Front Oncol 9:1346

    Article  PubMed  PubMed Central  Google Scholar 

  149. Fruge AD et al (2020) Fecal Akkermansia muciniphila is associated with body composition and microbiota diversity in overweight and obese women with breast cancer participating in a presurgical weight loss trial. J Acad Nutr Diet 120(4):650–659

    Article  PubMed  Google Scholar 

  150. Howe C et al (2018) Differential expression of tumor-associated genes and altered gut microbiome with decreased Akkermansia muciniphila confer a tumor-preventive microenvironment in intestinal epithelial Pten-deficient mice. Biochim Biophys Acta Mol Basis Dis 1864(12):3746–3758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Dingemanse C et al (2015) Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. Carcinogenesis 36(11):1388–1396

    Article  CAS  PubMed  Google Scholar 

  152. Weir TL et al (2013) Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 8(8):e70803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Kang CS et al (2013) Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One 8(10):e76520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Meng X et al (2020) Akkermansia muciniphila aspartic protease Amuc_1434* inhibits human colorectal cancer LS174T cell viability via TRAIL-mediated apoptosis pathway. Int J Mol Sci 21(9):3385

    Article  CAS  PubMed Central  Google Scholar 

  155. Salgia NJ et al (2020) Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol 78(4):498–502

    Article  CAS  PubMed  Google Scholar 

  156. Huang K et al (2015) Biochemical characterisation of the neuraminidase pool of the human gut symbiont Akkermansia muciniphila. Carbohydr Res 415:60–65

    Article  CAS  PubMed  Google Scholar 

  157. Ottman N et al (2017) Genome-scale model and omics analysis of metabolic capacities of Akkermansia muciniphila reveal a preferential mucin-degrading lifestyle. Appl Environ Microbiol 83(18):e01014–e01017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Santoni M et al (2018) Re: gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Eur Urol 74(4):521–522

    Article  PubMed  Google Scholar 

  159. Hinnebusch BF et al (2002) The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132(5):1012–1017

    Article  CAS  PubMed  Google Scholar 

  160. Park J et al (2015) Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 8(1):80–93

    Article  CAS  PubMed  Google Scholar 

  161. Wang Y et al (2021) Sini decoction ameliorates colorectal cancer and modulates the composition of gut microbiota in mice. Front Pharmacol 12:609992

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Dizman N et al (2021) Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Med 10(1):79–86

    Article  CAS  PubMed  Google Scholar 

  163. Teng L et al (2020) HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila. Pharmacol Res 160:105086

    Article  CAS  PubMed  Google Scholar 

  164. Xu X et al (2020) Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Front Microbiol 11:814

    Article  PubMed  PubMed Central  Google Scholar 

  165. Zhou X et al (2020) Effect and mechanism of vitamin D on the development of colorectal cancer based on intestinal flora disorder. J Gastroenterol Hepatol 35(6):1023–1031

    Article  CAS  PubMed  Google Scholar 

  166. Sfanos KS et al (2018) Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 21(4):539–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Jones GR, Molloy MP (2021) Metformin, microbiome and protection against colorectal cancer. Dig Dis Sci 66(5):1409–1414

    Article  CAS  PubMed  Google Scholar 

  168. Lim SH, Dutta D, Moore J (2019) Rifaximin for sickle cell disease. Am J Hematol 94(12):E325–E328

    Article  PubMed  Google Scholar 

  169. Grajeda-Iglesias C et al (2021) Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging (Albany NY) 13(5):6375–6405

    Article  CAS  Google Scholar 

  170. Shi L et al (2020) Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J Immunother Cancer 8(2):e000973

    Article  PubMed  PubMed Central  Google Scholar 

  171. Liu MN et al (2020) [Effects of Akkermansia muciniphila on the proliferation, apoptosis and insulin secretion of rat islet cell tumor cells]. Sichuan Da Xue Xue Bao Yi Xue Ban 51(1):13–17

    Google Scholar 

  172. Zheng Y et al (2019) Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 7(1):193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Greer RL et al (2016) Akkermansia muciniphila mediates negative effects of IFNgamma on glucose metabolism. Nat Commun 7:13329

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Peng M et al (2016) Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354(6311):481–484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Dighe AS et al (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1(6):447–456

    Article  CAS  PubMed  Google Scholar 

  176. Jorgovanovic D et al (2020) Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res 8:49

    Article  PubMed  PubMed Central  Google Scholar 

  177. Hanada T et al (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203(6):1391–1397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Zou Q et al (2015) T cell intrinsic USP15 deficiency promotes excessive IFN-gamma production and an immunosuppressive tumor microenvironment in MCA-induced Fibrosarcoma. Cell Rep 13(11):2470–2479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Slotkin W, Nishikura K (2013) Adenosine-to-inosine RNA editing and human disease. Genome Med 5(11):105

    Article  PubMed  PubMed Central  Google Scholar 

  180. Mager LF et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369(6510):1481–1489

    Article  CAS  PubMed  Google Scholar 

  181. Wang T et al (2020) Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction. Nat Metab 2(7):635–647

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Arun Prasath Lakshmanan and Selvasankar Murugesan contributed equally.

Authors and Affiliations

  1. Research Department, Sidra Medicine, Doha, Qatar

    Arun Prasath Lakshmanan, Selvasankar Murugesan & Dhinoth Kumar Bangarusamy

Authors
  1. Arun Prasath Lakshmanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Selvasankar Murugesan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dhinoth Kumar Bangarusamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Arun Prasath Lakshmanan or Selvasankar Murugesan .

Editor information

Editors and Affiliations

  1. Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Jammu and Kashmir, India

    Muzafar Ahmad Macha

  2. Molecular and Metabolic Imaging Laboratory, Sidra Medicine, Doha, Qatar

    Ajaz Ahmad Bhat

  3. Department of Biotechnology, Central University of Kashmir, Ganderbal, Jammu and Kashmir, India

    Nissar Ahmad Wani

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lakshmanan, A.P., Murugesan, S., Bangarusamy, D.K. (2022). Crosstalk of Immuno-Oncology and Metabolism: Influence of Akkermansia muciniphila and Personalized Therapy Approach. In: Macha, M.A., Bhat, A.A., Wani, N.A. (eds) Immuno-Oncology Crosstalk and Metabolism. Springer, Singapore. https://doi.org/10.1007/978-981-16-6226-3_4

Download citation

Publish with us

Policies and ethics

Search

Navigation